Navigation Links
INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale
Date:10/30/2009

ectively stimulate alpha-2A adrenoreceptors in the prefrontal cortex. Stimulation of the postsynaptic alpha-2A receptors is thought to strengthen working memory, reduce susceptibility to distraction, improve attention regulation, improve behavioral inhibition, and enhance impulse control.

Once-daily INTUNIV is expected to be available in US pharmacies in November and will come in four dosage strengths (1 mg, 2 mg, 3 mg, and 4 mg). INTUNIV is not a controlled substance and has no known potential for abuse or dependence.

INTUNIV Demonstrated Significant Symptom Reduction in Patients Diagnosed with ADHD and the Presence of Oppositional Symptoms

This randomized, placebo-controlled, flexible-dose study was conducted in 214 patients ages 6 to 12 over a nine-week period. INTUNIV demonstrated significant ADHD symptom improvement in the primary and secondary measures as demonstrated on the Oppositional Subscale of the CPRS-R:L and the ADHD Rating Scale-IV (ADHD-RS-IV), respectively. The CPRS-R:L is a comprehensive scale that uses parent observer and self-report ratings to help assess ADHD symptoms and behaviors in children. At the study's end, patients taking INTUNIV showed significant symptom reduction as compared to patients taking placebo (-10.9 versus -6.8; effect size 0.59; P<.001) when assessed using the oppositional subscale of the CPRS-R:L. The ADHD-RS-IV scale assesses hyperactive, impulsive, and inattentive ADHD symptoms. ADHD-RS-IV mean change from baseline for INTUNIV versus placebo was -23.8 versus -11.5; effect size 0.92; P<.001. In this study, most treatment-emergent adverse events were mild to moderate. The most commonly reported treatment-emergent adverse events in patients taking INTUNIV (greater than or equal to 10 percent) were somnolence, headache, sedation, upper abdominal pain, and fatigue.

Dr Sallee added, "The data presented today provide additional support for the safety and efficacy profile of INTUNIV
'/>"/>

Contact: Matt Cabrey
mcabrey@shire.com
484-595-8248
Porter Novelli
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Shires INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
2. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
3. Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile
4. Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products
5. New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
6. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
7. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
8. New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women
9. How embryonic stem cells develop into tissue-specific cells demonstrated
10. ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
11. Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...re recruited annually to participate in clinical t... Protection (AHRP), and most will be compensated f...ons view payments to volunteers as compensation fo...tial risks related to participating in the experim...a very different view of clinical trial compensati...
(Date:12/4/2009)... immediately or 3 weeks later, study shows , ...f surgical repair or reconstruction of multiple-li...e, a new study has found. , Multiple-ligament k...ns that can occur in high-impact car crashes or in...ry to repair these injuries hasn,t been definitive...
(Date:12/4/2009)...e/ -- Substantial progress has been made over the ...y to diagnose and treat epilepsy and its complicat...s not reached most of the 50 million people around...lion people in the United States who have the diso..., president of the American Epilepsy Society (AES)...
(Date:12/4/2009)...k during winter isn,t known, CDC says, , ...of states reporting widespread swine flu activity ...h of 48 just two weeks ago, a U.S. health official...wine flu vaccine continues to increase, Dr. Thomas...ase Control and Prevention, said during an afterno...
(Date:12/4/2009)...hesitate to take breast cancer drug, study finds ,...rries about side effects are a major reason why on...east cancer are willing to take the drug tamoxifen...n an effort to inform women about the risks and be... of Michigan Comprehensive Cancer Center created a...
Breaking Medicine News(10 mins):Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4Health News:Swine Flu Continues to Wane 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2
...ck claims status, rate doctors and ...0 Regence,s innovative Web site,that allows membe...r doctor,and earn gift certificates for participat... 2,400 Web sites representing 47 countries in 96 c...
... Service Provider Grows 352%, ATLANTA, Sept. 30 ...lth care business process outsourcing, today annou...of the fastest-growing privately held,companies in... companies that made the list reported aggregate r...
...perability Requirements, SUNNYVALE, Calif., Sept....nformation Technology (CCHIT(R)) today announced,t... Certified(R) 08,Ambulatory EHR and meets the Cert...ere most Americans get their,healthcare. The Commi...
...han Two Lbs. Folds Flat For Easy ... 30 Committed to,providing smart, easy fitness so...o, Perfect Pushup, LLC ( http://www.perfectpushup....eled after the,successful Perfect Pushup unit that...
...LC, a professional software development firm, toda...Analyst, an innovative and full-featured Contract ... more intuitive look and feel User Interface; Extr...ch any table on any lookup item, date ranges, and ...
...004 petition from,the Beverage Institute for Healt...-Cola Company (NYSE: KO ), the US Food and Drug A...ended its osteoporosis risk reduction health,claim...nition of the populations that could benefit from ...
Other Medicine News:Health News:myRegence.com Earns Best Health Care Industry Web Site Award 2Health News:RevenueMed Named to Inc. 5000 2Health News:MedPlexus Electronic Health Record Receives 08 CCHIT Certification 2Health News:MedPlexus Electronic Health Record Receives 08 CCHIT Certification 3Health News:MedPlexus Electronic Health Record Receives 08 CCHIT Certification 4Health News:Perfect Pushup Introduces Innovative Travel Fitness Solution; Mobile Unit Designed for Travelers Hits Retail This Month 2Health News:TrakSoft LLC Announces the Release of Contract Analyst, Version 3.0, a Contract Management System, which Includes a Major User Customization Upgrade 2Health News:TrakSoft LLC Announces the Release of Contract Analyst, Version 3.0, a Contract Management System, which Includes a Major User Customization Upgrade 3Health News:TrakSoft LLC Announces the Release of Contract Analyst, Version 3.0, a Contract Management System, which Includes a Major User Customization Upgrade 4Health News:Vitamin D Added to FDA Osteoporosis Risk-Reduction Health Claim 2Health News:Vitamin D Added to FDA Osteoporosis Risk-Reduction Health Claim 3Health News:Vitamin D Added to FDA Osteoporosis Risk-Reduction Health Claim 4
(Date:12/4/2009)..., , HOUSTON, Dec. 4 /PRNew...s of the AcceleDent System , which is an accelera... availability of a new Continuing Education course...professional education for many industries, includ... patient views about orthodontic treatment, a summ...
(Date:12/4/2009)..., , WILMINGTON, Del., Dec. 4 /PRNewswire...nounced that the US Food and Drug Administration (...etiapine fumarate) Extended Release Tablets as adj...dults with Major Depressive Disorder (MDD). SEROQU... by the FDA to treat both major depressive disorde...
(Date:12/3/2009)..., , MADISON, N.J., Dec. 3 /PRNewswire-Fi...a patient,s risk of developing a potentially life-...harmaceutical therapies or chemicals is one of sev...nostics leader Quest Diagnostics (NYSE: DGX ) wi...atology (ASH) Annual Meeting and Exposition, Decem...
Breaking Medicine Technology:AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Does Synthetic Biology Need Synthesized Ethics 3F 12760 1Does Synthetic Biology Need Synthesized Ethics 3F 12760 2Does Synthetic Biology Need Synthesized Ethics 3F 12760 3ChromaDex Establishes a Blanket Purchase Agreement With the National Institutes of Health 49869 1ChromaDex Establishes a Blanket Purchase Agreement With the National Institutes of Health 49869 2Report 3A Primary Care Doctors in Greatest Demand 49865 1Report 3A Primary Care Doctors in Greatest Demand 49865 2
...D, Wash., April 23 Archus Orthopedics, Inc.,annou...first human implant,of its TFAS-C(TM) system, the ...treating spinal stenosis, a condition in which deg...mpression of spinal nerves producing,neurological ... moderate to,severe spinal stenosis undergo decomp...
...EGO, April 23 Vical Incorporated,(Nasdaq: VICL )...ations,nationwide of an independently produced vid...reated with the company,s Allovectin-7(R),immunoth...d to be used,broadly by stations in cities with cl...vectin-7(R) trial, and in other cities by stations...
Other Medicine Technology:First Human Implant of New Archus Orthopedics Facet Replacement System 2Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report 2Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report 3Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report 4Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report 5
ManuTrain
... combines the therapeutic benefits of controlled c...and cold to minimize pain. The versatile design of... hand coverage. ,For added support, support bars ... a wider range of motion is desired.,All Cryo/Cuf...
Cindy Wrist Support
...nel Splint immobilizes and positions the elbow at ...tricts full extension and flexion to minimize stre...and irritation due to contracture. Also for ulnar ...high-density beige polyethylene shell with plush 3...
Medicine Products: